Navigation Links
MDS Pharma Services Launches Next Generation Phase I Study Management System
Date:7/7/2008

Proprietary ClinQuick(R) system builds on a 15-year track record of

technical leadership in early clinical research

KING OF PRUSSIA, PA, July 7 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has launched the next generation of its proprietary ClinQuick(R) electronic system for Phase I study set-up, data capture, project tracking and personnel credential management. Aimed at improving client service, the new version of the ClinQuick(R) system extends a 15-year legacy of technical leadership in early clinical research. System enhancements include a more user-friendly interface, improved menu navigation and a more robust data platform. This new platform will enable faster and more flexible reporting and will ultimately allow clients to access their data via the internet.

"Since its implementation in 1993, ClinQuick(R) has been used successfully in more than 3,000 Phase I studies involving nearly 100,000 participants," said MDS Pharma Services President David Spaight. "Our investment to enhance the ClinQuick(R) system builds on that legacy of success and will allow us to meet growing client demand for early clinical research services while maintaining our leadership position in Phase I. This next-generation ClinQuick(R) system will further improve our ability to deliver high quality Phase I services on time."

About ClinQuick(R)

Designed and built by MDS Pharma Services for use in its Phase I clinical research centers, the fully integrated ClinQuick(R) system facilitates rapid data cleansing and client monitoring for seamless operation of both single and multi-site studies. ClinQuick(R) accelerates timelines, enables accurate direct data acquisition, and reduces costs by a third compared to traditional paper case report forms (CRFs) - the forms used by clients to collect and document data from each participating clinical research site. The system is fully CFR Part 11 compliant and can be used for study management and electronic data capture (EDC), either alone or in conjunction with a client-provided EDC system or paper CRFs. MDS Pharma Services offers one of the world's largest capacities for conducting early-phase clinical studies, with some 1,100 beds in five state-of-the-art clinical research facilities in North America and Europe.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at http://www.mdsps.com.

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... "I have gout, and I wanted to treat it naturally," said an ... relieve gout and pain caused by varicose veins. I drank it every morning for ... what VA doctors called the worst sinusitis case they'd seen and relieved gas, stress ...
(Date:12/9/2016)... ... 2016 , ... Mediaplanet today announces distribution of the latest edition of “Transplants,” ... up as an organ donor for the 123,000 people in the United States who ... save up to 8 saves through organ donation and enhance many others through tissue ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... through the Pennsylvania Cable Network (PCN) during the summer of 2016. The program ... Grant provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
Breaking Medicine Technology: